

File No. 250879

Committee Item No. 8

Board Item No. 2

COMMITTEE/BOARD OF SUPERVISORS

AGENDA PACKET CONTENTS LIST

Committee: Government Audit and Oversight
Board of Supervisors Meeting:

Date: September 18, 2025

Date: September 30, 2025

Cmte Board

- | | | |
|-------------------------------------|-------------------------------------|--|
| ☐ | ☐ | Motion |
| ☒ | ☒ | Resolution |
| ☐ | ☐ | Ordinance |
| ☐ | ☐ | Legislative Digest |
| ☐ | ☐ | Budget and Legislative Analyst Report |
| ☐ | ☐ | Youth Commission Report |
| ☐ | ☐ | Introduction Form |
| ☐ | ☐ | Department/Agency Cover Letter and/or Report |
| ☐ | ☐ | MOU - FY2022-2024 - Clean |
| ☐ | ☐ | MOU - FY2022-2024 - Redline |
| ☐ | ☐ | Grant Information Form |
| ☐ | ☐ | Grant Budget |
| ☐ | ☐ | Subcontract Budget |
| ☐ | ☐ | Contract / DRAFT Mills Act Agreement |
| ☐ | ☐ | Form 126 – Ethics Commission |
| ☐ | ☐ | Award Letter |
| ☐ | ☐ | Application |
| ☐ | ☐ | Public Correspondence |

OTHER

☐	☐	_____
☐	☐	_____
☐	☐	_____
☐	☐	_____
☐	☐	_____
☐	☐	_____
☐	☐	_____
☐	☐	_____

Prepared by: Monique Crayton
Prepared by: Monique Crayton
Prepared by: _____

Date: September 26, 2025
Date: September 12, 2025
Date: _____

1 [Settlement of Unlitigated Claims against Alvogen, Inc., et al. - City to Receive Approximately
2 \$1,200,000 to \$2,000,000 Over 10 Years]

3 **Resolution authorizing settlement of unlitigated claims on behalf of the City and**
4 **County of San Francisco and the People of the State of California against Alvogen, Inc.;**
5 **Amneal Pharmaceuticals, Inc.; Apotex Inc.; Hikma Pharmaceuticals USA Inc.; Indivior**
6 **Inc.; Mylan Pharmaceuticals Inc.; Sun Pharmaceutical Industries, Inc.; and Zydus**
7 **Pharmaceuticals (USA), Inc. for abatement funds in the range of \$1,200,000 to**
8 **\$2,000,000 to be paid over 10 years; the claims relate to settling companies' allegedly**
9 **improper and unlawful practices, which contributed to the epidemic of opioid abuse**
10 **and misuse and caused a public nuisance.**

11
12 WHEREAS, Alvogen, Inc.; Amneal Pharmaceuticals, Inc.; Apotex Inc.; Hikma
13 Pharmaceuticals USA Inc.; Indivior Inc.; Mylan Pharmaceuticals Inc.; Sun Pharmaceutical
14 Industries, Inc.; and Zydus Pharmaceuticals (USA), Inc. ("Settling Manufacturers") and several
15 States have agreed to a national settlement agreement that resolves numerous governments'
16 claims against the Settling Manufacturers for their allegedly improper and unlawful practices,
17 which contributed to the epidemic of opioid abuse and misuse and caused a public nuisance;
18 and

19 WHEREAS, San Francisco has not filed a lawsuit against the Settling Manufacturers,
20 but may participate in the Settling Manufacturers national settlement agreement by releasing
21 potential claims against the Settling Manufacturers relating to their marketing and distribution
22 of opioids in exchange for payments totaling approximately \$1,200,000 to \$2,000,000; and

23 WHEREAS, The City Attorney has recommended settlement by releasing potential
24 claims against the Settling Manufacturers relating to their marketing and distribution of opioids
25 in exchange for the payment of abatement funds from the Settling Manufacturers to San

1 Francisco, in an amount estimated to be approximately \$1,200,000 to \$2,000,000 over the
2 next 10 years; now, therefore, be it

3 RESOLVED, That Pursuant to Charter, Section 6.102(5) and Administrative Code,
4 Section 10.24(b), the Board of Supervisors hereby authorizes the City Attorney to settle
5 potential claims against Alvogen, Inc.; Amneal Pharmaceuticals, Inc.; Apotex Inc.; Hikma
6 Pharmaceuticals USA Inc.; Indivior Inc.; Mylan Pharmaceuticals Inc.; Sun Pharmaceutical
7 Industries, Inc.; and Zydus Pharmaceuticals (USA), Inc. relating to their marketing and
8 distribution of opioids by the payment of abatement funds from marketing and distribution of
9 opioids to San Francisco, in an amount estimated to be approximately \$1,200,000 to
10 \$2,000,000 over the next 10 years.

11
12
13 APPROVED AS TO FORM AND
RECOMMENDED:

14
15 /s/ Sara J. Eisenberg
16 SARA J. EISENBERG
Chief of Complex and Affirmative Litigation

17
18 n:\cpu\li2023\190034\01657182.docx
19
20
21
22
23
24
25